Compare Phillips 66 (PSX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs Tango Therapeutics Inc. — how do they compare? Phillips 66 trades at $297 (market cap $116.81B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Phillips 66 is far larger — about 31.1× Tango Therapeutics Inc.'s market cap, and Phillips 66 pays a 1.74% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Phillips 66 for 63 Days and Tango Therapeutics Inc. for 0 Days on average.
| PSX | TNGX | |
|---|---|---|
Market Cap | $116.81B | $3.75B |
Volume | 2,609,145 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $297.29 | $32.90 |
52-Week Low | $127.75 | $7.50 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $133.27B | $2.77B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Phillips 66 (PSX) trades at $297.29, up 5.62% on the day, showing strong momentum near recent highs. The stock demonstrates solid fundamentals with a P/E of 16.71 and P/S of 0.78, while recent earnings beats and a 24.02% ROE highlight operational strength. Technical indicators show bullish momentum with the current price above key support levels. Recent news highlights structural advantages in refining margins and AI implementation for operational efficiency.
PSX presents a compelling investment case with strong profitability metrics and positive analyst sentiment (54% buy ratings), though current price exceeds the $286.90 consensus target. Key risks include refining margin volatility and potential policy impacts on diesel exports. The company's debt reduction progress and projected 2026 net cash flow of $3.0B support the bullish outlook despite competitive pressures.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
